Kyntra Bio Inc

KYNB

Healthcare Biotechnology

Kyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.

Revenue
n/m
EPS
n/m
Free cash flow
n/m

Quarter to June 2026, against a year earlier

3.44 0.15 −4.18%
Market cap
$14.5M
P/E
0.1×
Fwd P/E FY26e
n/m
Dividend yield
—
F-score
5/9
ROIC
0.00%
Net debt / EBITDA
2.0×
Payout ratio
—

Ratios over time FY16 to FY25

Returns on capital

ROIC was 0.0% in FY25, the highest of these ten years.

ROEROIC
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
ROE−31.2%−33.4%−16.1%−14.5%−38.8%−86.5%−258.0%307.0%24.5%−165.2%
ROIC−162.2%0.0%−360.7%−142.2%0.0%0.0%0.0%0.0%0.0%0.0%

Debt

Net debt is 1.97× a year’s EBITDA.

Net debt / EBITDA
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Net debt / EBITDA3.8×5.8×6.4×6.9×3.9×1.1×1.1×0.4×−0.2×2.0×

Cash cycle, in days

Customers pay in 12 days, inventory is held 2457 days and suppliers are paid in 2458. Cash is tied up for 11 days between paying for goods and being paid.

Cash cycleDays to pay suppliersDays to be paid
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Cash cycle2124109295−253166216168−3911
Days to pay suppliers0001937102074055414541192458
Days to be paid21241094087274240612

Per share, from FY16

Since FY16, per share: revenue has fallen 34.6% a year.

Free cash flowRevenueBook value
FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25
Free cash flow1.0×−11.0×−10.7×−10.4×9.3×−13.0×−21.1×−35.0×−14.7×−0.5×
Revenue1.0×0.6×0.9×1.0×0.7×0.9×0.5×0.2×0.1×0.0×
Book value1.0×2.7×2.3×2.2×1.8×0.9×0.0×−0.7×−0.7×−0.1×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.19
Piotroski F-Score
5 3 4 3 3 2 1 2 2 5
Altman Z-Score
1.89 5.53 6.23 6.44 3.85 (1.39) (3.07) (8.08) (14.08) (20.33)
P/S ratio
7.30 28.25 18.27 14.48 18.90 5.53 10.61 0.55 1.79 5.51
Altman Z″-Score (non-manufacturers)
(0.54) 3.31 2.74 2.65 0.50 (5.28) (9.28) (17.85) (32.01) (45.38)
P/FCF ratio
228.22 0.00 0.00 0.00 42.94 0.00 0.00 0.00 0.00 0.00
Beneish M-Score
(3.60) (3.19) 2.29 (2.67) (3.66) (1.66) (3.87) (3.39) (3.55) (4.57)
P/Operating CF
(72.07) (3,120.12) (222.75) (82.48) (461.08) (23.69) (28.42) (4.41) (1.74) (1.94)
P/B ratio
7.63 6.76 7.36 6.94 7.55 5.68 0.00 0.00 0.00 0.00
EV/Sales
6.44 23.38 15.81 12.60 15.23 4.31 8.37 (0.26) 2.95 14.55
EV/EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00
EV/FCF
201.61 (40.83) (40.08) (38.28) 34.60 (9.02) (6.38) 0.12 (0.64) (19.47)
Current Ratio
4.09 8.71 7.75 6.84 4.63 2.10 1.80 1.52 1.47 3.39
Net Debt/EBITDA
3.78 5.83 6.40 6.94 3.90 1.10 1.13 0.41 (0.15) 1.97
Debt/Equity
0.56 0.18 0.20 0.07 0.06 0.46 (65.30) (0.39) (0.36) 0.00
ROE
(31.22%) (33.44%) (16.06%) (14.47%) (38.76%) (86.50%) (258.01%) 307.01% 24.48% (165.18%)
ROA
(12.35%) (17.67%) (9.71%) (8.86%) (22.48%) (36.24%) (42.44%) (55.00%) (14.91%) 109.81%
ROIC
(162.20%) 0.00% (360.67%) (142.19%) 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(17.86%) (15.25%) (11.87%) (11.98%) (30.26%) (104.76%) (122.42%) (239.50%) (75.28%) 262.71%
Average Days of Receivables
20.82 23.55 109.15 40.48 86.70 26.99 42.27 39.94 5.93 12.24
Earnings Yield
(4.60%) (3.39%) (2.23%) (2.05%) (5.72%) (22.27%) (19.69%) (352.67%) (90.63%) 517.88%
Free Cash Flow Yield
0.44% (2.03%) (2.16%) (2.27%) 2.33% (8.63%) (12.37%) (393.54%) (258.97%) (13.56%)
Free Cash Flow per Share
2.33 (25.69) (24.98) (24.37) 21.59 (30.43) (49.33) (81.59) (34.29) (1.19)
Book value per Share
69.77 187.61 157.17 154.50 122.82 62.02 (0.40) (47.19) (51.25) (4.21)
Free Cash Flow
5.86 (75.01) (83.98) (84.46) 77.61 (112.42) (184.67) (317.54) (137.22) (4.81)
EV/EBIT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.12 0.00 0.00
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026